DYN - Dyne Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

225.3M

Cash

207.7M

Avg Qtr Burn

-43.64M

Short % of Float

15.51%

Insider Ownership

1.31%

Institutional Own.

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
DYNE-251 Details Duchenne muscular dystrophy	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DYNE-101 Details Myotonic Dystrophy Type 1	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.